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Summary Phospholipids from malignant, benign and noninvolved human breast tissues were extracted by
chloroform-methanol (2:1) and analysed by 31P MR spectroscopy at 202.4 MHz. Thirteen phospholipids were
identified as constituents of the profiles obtained among the 55 tissue specimens analysed. Observed patterns in
phospholipid tissues profiles were distinct, allowing qualitative characterisation of the three tissue groups.
Multivariate analysis oflysophosphatidylcholine (LPC) and an uncharacterised phospholipid were shown to be
independently significant in predicting benign tissue histology as either fibrocystic disease or fibroadenoma in
92% of cases. Univariate analysis of relative.mole-percentage of phosphorus concentrations of individual
phospholipids using the Scheffe comparison procedure revealed that in malignant tissues, phosphatidylethanol-
amine was significantly elevated compared to benign (+ 32%) and noninvolved tissues (+ 22%). Phosphati-
dylinositol (+ 33%) and phosphatidylcholine plasmalogen (PC plas) (+ 25%) were increased in malignant
compared to benign ahd LPC was decreased (- 44%) in malignant compared to noninvolved. LPC was
significantly depressed (- 39%) in benign tissue compared to normal. Phospholipid indices computed to
further characterise the three tissue groups showed PC plas/PC elevated in malignant tissue compared to
benign and PE plas/PE depressed in malignant tissue compared to noninvolved. These findings support
previous investigations reporting that the alkyl-phospholipid analogues of phosphatidylcholine are released by
malignant tissues and that levels of ethanolamine are elevated in malignant tissues. Indices describing the
choline-containing phospholipids showed that these lipids are depressed significantly in malignant tissue
relative to healthy tissue.
Phosphorus-31 magnetic resonance spectroscopic studies of
malignant tissues have assessed phospholipid metabolism
through the phospholipid precursors and products found in
aqueous tissue extracts, namely phosphorylcholine and phos-
phorylethanolamine (Daly et al., 1987; Guidoni et al., 1987).
These two principle precursor-products of phospholipid
metabolism can be measured in analytical MR studies of
perchloric acid extracts of human breast tissues (Merchant et
al., 1988). These same two metabolites also contribute the
majority of the signal detected in the phosphomonoester
spectral region of intact cells and of in vivo MR analysed
human breast tissues (Ronen et al., 1988; Sijens et al., 1988).
Evaluated in this manner, these cytoplasmic components
reveal little detail concerning the biochemistry of the corre-
sponding membrane phospholipids in which they are incor-
porated.
Because phospholipids are a major component of the cell
membrane, assessment of phospholipid metabolism in malig-
nant tissues is important for understanding tumour growth
(Rozengurt et al., 1979). Coman et al. (1944) showed that
alterations in membrane metabolism and composition result
in phenomena which lead to uncontrolled growth and loss of
intracellular communication. Patton and Jensen (1975) show-
ed that metastasis may be directly linked to alterations in cell
membranes while other groups showed that phospholipids
are important for the immune system's response to tumour
growth (Hefta et al., 1988; Low et al., 1988; Freddo et al.,
1986).
Development of an analytical MR phospholipid analysis
may be helpful in the diagnostic process. Such an analysis
might, through characteristic differences in spectral profiles,
enable differentation of normal, benign, premalignant, and
malignant breast tissues. This study profiles the phospho-
lipids from normal, benign and malignant surgical breast
tissue specimens with the intention of contributing to the
understanding of the biochemistry of neoplastic processes in
the human breast and advancing the role of magnetic reson-
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ance spectroscopy in differentiating malignant and benign
lesions of the breast.
Materials and methods
Surgery
Human breast tissue specimens were obtained from patients
undergoing scheduled surgical procedures. These unfixed tis-
sue specimens were divided within 10 min into their diseased
and nondiseased components for histopathologic examina-
tion and MR spectroscopic phospholipid analysis. Portions
taken for MR analysis were then submerged in liquid nitro-
gen for storage. Specimens ranged from 0.2 to 1.5 g. The
remaining surgical tissue specimens were sectioned and exam-
ined microscopically for histologic diagnosis after staining
with hematoxylin and eosin.
Human breast tissue classification
Tissue specimens acquired for this study represent a variety
of pathological conditions and were classified for purposes of
univariate analysis as either malignant, benign or noninvolv-
ed breast parenchyma. Breakdown of these individual groups
reveals 18 malignant specimens with a primary diagnosis of
infiltrating adenocarcinoma; 25 benign specimens with pri-
mary diagnoses of benign conditions including fibrocystic
disease and fibroadenoma; and 12 specimens of noninvolved
breast parenchyma corresponding to ten noninvolved com-
ponents of malignant and two corresponding noninvolved
components of the benign specimens. The benign tissue speci-
mens were further classified according to reported histology
as fibrocystic disease and fibroadenoma for a separate multi-
variate analysis. The term 'noninvolved breast parenchyma'
indicates that the tissue specimen was obtained beyond the
margins of neoplastic tissues identified in the acquired breast
tissue specimen. The term noninvolved breast parenchyma
defines the essential and distinct tissue of the breast which is
composed primarily ofthe glands and ducts. Note that speci-
mens used in this study were from patients with no previous
history of malignancy.
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Chemical procedures
A simple modified Folch extraction was used to extract the
intracellular and membrane phospholipids (Folch et al., 1957;
Meneses et al., 1988). Breast tissue specimens frozen in liquid
nitrogen were weighed and pulverised to a fine powder with a
stainless steel mortar and pestle chilled with liquid nitrogen.
The homogenised tissue was added to 20 weight-volumes
(1 gm =1 ml) of chloroform-methanol 2:1 (v/v). The homo-
genate, having only one liquid phase, was filtered into a
separatory funnel and washed with 0.2 volume of 0.1M KCI
and allowed to separate thoroughly (ca. 24 h) at 24°C. The
chloroform phase, was recovered and evaporated at 37°C
using a rotary evaporator. The analytical medium for the31P
magnetic resonance phospholipid analysis was identical to
that previously described for MR phospholipid analysis
(Meneses et al., 1988). The medium consists-of reagent grade
chloroform and methanol containing benzene-d6 and dis-
solved Cs-EDTA, pH 6.0. The prepared lipid that is free of
excess solvents and not contaminated with excessive amounts
of paramagnetic cations or free-radicals, was dissolved in
2.0ml 2:1 chloroform-methanol containing benzene-d6 and
placed in a 10 mm MR sample tube. A single phase was then
obtained. To this solution, 1.0 ml of the Cs-EDTA salt was
added and the mixture stirred. Two phases were obtained, a
major chloroform phase and a minor water phase. The
Teflon plug of the MR sample tube was advanced expulsing
the minor water phase which was then removed. The MR
sample tube turbine was adjusted so that only the chloroform
phase was detected by the MR spectrometer's receiver coil.
31p Magnetic resonance spectroscopy
The MR spectrometer used in this investigation was a hetero-
nuclear GE 500NB system operating at 202.4 MHz for 31P.
The spectrometer was equipped with an Oxford Instruments
500/52 magnet and cryostat, having an operating magnetic
field of 11.75 Tesla, deuterium field-frequency stabilisation,
and an automatic field-homogeneity adjustment capability
that adjusted the spectrometer room temperature shims to
improve field homogeneity during sample acquisition. Analy-
tical samples were placed in standard 10 mm MR sample
tubes and spun at 8 Hz during the data acquisition period.
Samples were analysed with proton broad-band decoupling
to eliminate 'H-31P MR multiplets. Under these conditions
each spectral resonance corresponds! to a single phosphorus
functional group, representing a single generic phospholipid
species. Chemical shift data are reported relative to the stan-
dard of 85% inorganic orthophosphoric acid (Glonek et al.,
1974); however, the primary internal reference standard was
a naturally occurring phospholipid phosphatidylcholine
(chemical shift, -0.84 6). Spectrometer conditions used for
analytical extract analyses were as follows: pulse sequence,
one pulse; pulse width, 181s s (450 spin-flip angle); acquisition
delay, 5001 s; cycling delay 500 m s; number of acquisitions,
12000; number of points per free-induction decay, 4096;
acquisition time 1.02s; sweep width ± 1000 Hz. The total
average time per analysis was 6 h. In addition, a computer
generated filter time-constant introducing 0.6 Hz line broad-
ening was applied. Data reductions, including peak area and
chemical shift measurements and spectral curve analysis,
were calculated using the spectrometer's computer. To com-
pensate for relative saturation effects among various phos-
phorus signals detected in a single 31P MR spectroscopic
profile, the MR spectrum must be standardised against measur-
ed amounts of tissue-profile metabolites wherever these are
known. The rapid cycling time used necessitates calibration
of the instrument with known materials appropriately doped
to obtain calibrated spectra. The procedures for carrying out
this calibration so that an accurate quantitative measurement
is obtained from the 31P MR spectral profile have been
described (Meneses et al., 1989; Greiner et al., 1981; Burt et
al., 1976; Barany et al., 1982). Chemical shifts follow the
convention of the International Union of Pure and Applied
Chemistry and are reported in field independent units of 6.
Data analyses
Metabolite concentrations in relative phosphorus mole
percentages were computed for all detected phospholipid
resonances in the analysed breast tissue specimens. Mean
metabolite concentrations in relative mole percentages of
phosphorus were calculated for the malignant, benign and
noninvolved tissue groups. Initially, the three groups were
compared at the level of the individual phospholipids by an
analysis of variance. For those resonances where significance
was determined to exist (F probability, P<0.05) post-hoc
simple and complex contrasts were applied. Simple contrasts
employed the Scheffe comparison procedure. Complex con-
trasts pitted the combined means of two tissue groups against
the remaining mean to which a simple two-tailed t- test was
applied (SPSS Inc, 1986). Significance was measured at the
P<0.05 and P<0.01 levels for both post hoc comparison
procedures. Under most conditions analysis of variance
requires the assumption that the underlying variances
between tested means are equal. At those resonances where
significance was found to exist, homogeneity of variance was
confirmed using Cochran's C and the Bartlett-Box F tests.
From the grouped metabolite data, 19 indices representing
phospholipid metabolism were calculated: PC + PE; PC plas
+ PE plas; (PC plas + PE plas)/(PC + PE); PC plas/PC; PE
plas/PE; LECITHIN, PC + PC plas; CHOLINE, PC + PC
plas + SPH; LECITHIN/CEPHALIN, (PC + PC plas)/(PE +
PE plas); OUTSIDE, PC + SPH; INSIDE, PE + PS; LEAF-
LET, (PC + SPH)/(PE + PS); PC/PE; PC/PS, SPH/PS; SPH/
PE; ANIONIC/NEUTRAL, (PI + PS + CL + PA + PG)/
(PC + PC plas + SPH + PE + PE plas); LYSO, LPC + LPE;
LPC/PC; LPE/PE. These theoretical parameters, given as
ratios of individual or grouped phospholipids were generated
to compare phospholipids or groups of phospholipids and
provide more pathway-specific metabolic interrelations for
discussion.
Benign breast tissue spectral data were analysed in a multi-
variate fashion. Using discrimination analysis, the variables
(relative concentrations of LPC, U and PA) were entered in a
forward, stepwise manner using P< 0.05 as criterion for
inclusion in the model. Phospholipids independently signi-
ficant in predicting benign tissue classification were deter-
mined.
For purposes of statistical analysis, missing values repre-
sent resonance signals lying below the levels of detection and
were not included in the analysis.
Results
31P MR phospholipid spectroscopic profiles of malignant,
benign and noninvolved human breast tissues are presented
in Figure 1. Thirteen resonance signals of the 31P spectra
were identified as arising from membrane phospholipids.
These resonance signals, from downfield, left to upfield right,
include: PG at 0.52 6, LPE at 0.43 6, PA at 0.32 6, CL at
0.18 6, U at 0.13 6, PE plas at 0.07 6, PE at 0.03 6, PS at
-0.05 6, SPH at -0.09 6, LPC at -0.27 6, PI at -0.37 6,
PC plas at -0.78 6 and PC at -0.84 6.
The relative signal intensities of the noninvolved breast
tissue phospholipid spectrum appear consistent in their
arrangement with the most prominent signal, PC, followed
successively in relative intensity by SPH, PE plas, PS, PE, PI
and other minor signals of variable intensity. This pattern is
consistent in the benign spectra, but not in the malignant. In
the malignant, the prominent PC peak is followed in relative
intensity by a pattern of PE plas, SPH, and PE in which PE
plas is most prominent of the three phospholipids in six
cases, SPH most prominent in seven cases and PE most
outstanding in five cases. PS is less prominent in all cases and
is followed in relative intensity by PI.
Ten of the 12 noninvolved breast tissue specimens analysed
were obtained from patients with diagnosed malignancy. Of
these ten specimens, five demonstrated trace amounts of PA,
LPC and U in various combinations, i.e. LPC appeared onlyEX VIVO 31p MRS OF BREAST 695
with PA and U present. PA did not appear in the remaining
five specimens which also lacked detectable LPC and U. An
appreciable characteristic of the noninvolved spectra was the
absence of detectable LPE and PG.
In the benign spectra, the 25 specimens were derived from
tissues with a primary diagnosis of fibrocystic disease in 13
Malignant
Benign
PG PA
Noninvolved
0.5 0.0 -0.5 -1.0
Figure 1 Phosphorus-31 magnetic resonance spectra ofextracted
phospholipids of malignant (top), benign (middle) and nonin-
volved (bottom) human breast tissue specimens. The resonance
signals from downfield (left) to upfield (right) are as follows:
phosphatidylglycerol (PG) at 0.52 6, phosphatidic acid (PA) at
0.32 6, cardiolipin (CL) at 0.18 6, an uncharacterised phos-
pholipid (U) at 0.13 6, phosphatidylethanolamine plasmalogen
(PE plas) at 0.07 6, phosphatidylethanolamine (PE) at 0.03 6,
phosphatidylserine (PS) at -0.05 6, sphingomyelin (SPH) at
-0.09 6, lysophosphatidylcholine (LPC) at -0.27 6, phosphati-
dylinositol (PI) at -0.37 6, phosphatidylcholine plasmalogen
(PC plas) at -0.78 6, phosphatidylcholine (PC) at -0.84 6.
cases and fibroadenoma in 12 cases. The pattern of concur-
rently appearing PA, LPC and the uncharacterised resonance
at 0.13 6 was seen exclusively in the fibrocystic group and
never in the fibroadenomas. Discrimination analysis using
LPC, U and PA as independent features to predict fibrocystic
disease vs fibroadenoma showed that LPC and U are inde-
pendently significant. This model, a linear discrimination
analysis, classified 92% of cases correctly by predicting the
histologic tissue type. PA was significant in univariate
analysis, however, when corrected for the contribution of
LPC and U in the multivariate analysis, it was found not to
be significant.
PA appeared in 14, LPC in 14 and the uncharacterised
resonance at 0.13 6 in 16 of the 18 malignant cases studied.
Other minor metabolites such as PG were also seen in these
tissues.
Evaluation of the MR spectra of the three groups shows
that quantitative spectral data (Table I) can be grouped into
four ranges of relative concentrations: greater than 40%, PC;
between 10 and 15%, PE plas and SPH; between 5 and 10%,
PS and PE; and less than 5%, the eight remaining phospho-
lipids. Among the remaining eight phospholipids, LPE was
not detected in normal tissue and presented a relative mean
concentration of less than 1% in malignant tissues. PG was
detected in only one normal tissue sample and comprised less
than 1% of neoplastic tissue phospholipids.
A post-hoc Scheffe comparison procedure, applied between
the means of the three tissue groups at the resonances ofPE,
LPC, PI and PC plas, following an analysis of variance,
demonstrated significant differences among the three tissue
groups (Table II, upper half). Malignant tissue is distinctly
different from benign at PE, PI and PC plas, all three
phospholipids are significantly elevated in malignant tissue by
factors of 1.32, 1.33 and 1.25 respectively. Malignant tissue
differed significantly from noninvolved at PE and LPC. PE
was elevated by a factor of 1.22 and LPC was diminished by
a factor of 0.44 in malignant tissue. Benign tissues differed
significantly from noninvolved at LPC. They were diminished
by a factor of 0.39 in benign.
Complex contrast of the individual phospholipids, compar-
ing the combined mean values of two tissue groups to the
remaining tissue group, (Table III, upper half), showed that
LPC and U were reduced and PE increased significantly in
neoplastic tissue compared to noninvolved. SPH and LPC
were significantly decreased in malignant tissue compared
with nonmalignant while PE, PI and PC plas were signifi-
cantly increased. Benign tissue differed significantly from the
combined malignant and noninvolved with decreases noted in
the resonances of PI and U.
To study patterns in the phospholipid metabolism of the
three tissue groups, 19 indices were calculated from the spec-
Table I 31p MR phospholipid profile of human breast tissues
Chemical Mean molepercentage ofphosphorus±s.d.
Phospholipida shift (6) Noninvolvedb Benignc Malignantd Fprobe
PC -0.84 42.26±3.32 43.31±3.54 41.10±3.71 0.14
LPC -0.27 2.13±0.75 1.30±0.52 1.21±0.52 O.Olf
PC plas -0.78 3.89±1.06 3.75±0.91 4.69±1.14 0.03g
PE 0.03 7.61±1.59 8.20±2.00 10.07±1.62 0.005f
LPEh 0.43 1.59±1.49 0.56±0.20 0.43
PE plas 0.07 12.45±3.25 11.79±2.91 11.07±2.77 0.44
PA 0.32 0.93±0.37 1.60±0.85 1.42±0.89 0.62
PS -0.05 9.71±1.28 8.73±2.04 8.29±1.72 0.17
SPH -0.09 13.36±3.13 13.40±3.50 10.46±3.42 0.08
PI -0.37 4.58±0.67 4.43±0.79 5.91±1.04 0.003f
U 0.13 3.79± 1.30 2.52±0.86 2.95±0.66 0.08
PGi 0.52 1.27 0.80±0.68 0.91±0.88 0.89
CL 0.18 3.94± 1.83 3.13±2.07 3.20±0.88 0.60
apC, phosphatidylcholine; LPC, lysophosphatidylcholine; PC plas, phosphatidyl-
choline plasmalogen; PE, phosphatidylethanolamine; LPE, lysophosphatidylethanol-
amine; PE plas, phosphatidylethanolamine plasmalogen; PA, phosphatidic acid; PS,
phosphatidylserine; SPH, sphingomyelin; PI, phosphatidylinositol; U, uncharacterised
phospholipid; PG, phosphatidylglycerol; CL, cardiolipin. bn = 12. cn =25. dn = 18. F
probability of analysis of variance. 'P<0.0i. 9P<0.05. hNot detected in noninvolved
tissues. 'Detectable in only one specimen of noninvolved tissue.696 T.E. MERCHANT et al.
Table H Significant simple contrasts of phospholipids and phos-
pholipid indices using Scheffe comparison procedures
Malignant Malignant vs Benign vs
Metabolite or Indexa vs benign noninvolved noninvolved
PE * *
LPC *
PI **
PC plas *
PC plas/PC *
PE plas/PE *
CHOLINE *
OUTSIDE **
LPC/PC * *
'PE, phosphatidylethanolamine; LPC, lysophosphatidylcholine; PI,
phosphatidylinositol; PC plas, phosphatidylcholine plasmalogen; PC,
phosphatidylcholine; PEplas, phosphatidylethanolamine plasmalogen;
CHOLINE, PC + PC plas + SPH (sphingomyelin); OUTSIDE, PC +
SPH; LPC, lysophosphatidylcholine. *P<0.05; **P<0.01.
Table Ill Post hoc tests performed as complex contrasts
Phospholipid or Noninvolved Malignant vs Benign vs combined
Indexa vs neoplastic nonmalignantmalignant andnoninvolved
PE * **
SPH *
LPC ** *
PI ** *
PC plas *
U * *
PC plas/PC ** *
PE plas/PE * **
CHOLINE **
OUTSIDE ** *
PC/PE *
SPH/PE *
LYSO * *
LPC/PC ** *
aPE, phosphatidylethanolamine; SPH, sphingomyelin; LPC, lyso-
phosphatidylcholine; PI, phosphatidylinositol; PC plas, phosphatidyl-
choline plasmalogen; U, uncharacterised phospholipid; PC, phos-
phatidylcholine; PE plas, phosphatidylethanolamine plasmalogen;
CHOLINE, PC + PC plas + SPH; OUTSIDE, (PC + SPH)/(PE +
PS); LYSO, LPC (lysophosphatidylcholine) + LPE (lysophosphati-
dylethanolamine). *P<0.05; **P<0.01.
tral data (Table IV). Following an analysis of variance and
intergroup comparision of the three tissue group indices
(Table II, lower half), it was found that malignant tissue had
a significantly higher PC plas/PC ratio than the benign tissue
and significantly lower CHOLINE and OUTSIDE indices
than benign. Malignant tissue has significantly depressed PE
plas/PE and LPC/PC ratios compared to noninvolved.
Similarly, in benign tissue the LPC/PC index was
significantly depressed compared with noninvolved.
The complex contrasts of all indices showed that for the
neoplastic tissues, PE plas/PE, LYSO and LPC/PC indices
were depressed compared to noninvolved tissues, and of the
indices PC plas/PC, PE plas/PE, CHOLINE, OUTSIDE,
PC/PE, SPH/PE and LYSO, all were significantly depressed
in malignant tissues compared with nonmalignant except for
PC plas/PC which was significantly increased. PC plas/PC
and LPC/PC were significantly diminished and OUTSIDE
significantly augmented in benign tissue compared with the
combined malignant and noninvolved tissues.
Discussion
The study of phospholipids in normal and pathological tis-
sues is important because it can reveal membrane modifica-
tions produced by altered cellular conditions. Knowledge of
these modifications is important for improvements in detec-
tion, diagnosis and techniques of intervention (Greig et al.,
1986). This investigation utilises the techniques developed by
Meneses and Glonek (1988) in their study of 31P MR spectra
of extracted phospholipids. The unique quality of these tech-
niques is derived from the fact that the complete phospho-
lipid profile of a tissue, including phospholipids such as
acyl-monoesters and diesters, can be separated by the proce-
dure of Folch, Lees and Sloane-Stanley (1957). Further, the
signal area in the MR spectrum represents the mole percen-
tage of phosphorus concentration of all detectable phos-
pholipids. Other methods such as thin-layer chromatography
or high-performance liquid chromatography have none of
these possibilities, since under the conditions of these proce-
dures some signals may be masked by others and these
procedures detect chemical characteristics such as double
bonds or C = 0 functional groups rather than the phos-
phorus atom (Meneses et al., 1988) making them less reliable
Table IV 31P MR phospholipid indices (±s.d.) ofhuman breast tissues
Phospholipid Index' Noninvolvedb Benignc Malignant' Fprobe
PC + PE 49.87±3.96 51.52±4.37 51.17±4.67- 0.56
PC plas + PE plas 16.35±3.49 15.55± 3.22 15.76± 3.07 0.78
(PC plas + PE plas)/(PC +PE) 0.32±0.06 0.30±0.05 0.31 ±3.40 0.60
PC plas/PC 0.09±0.02 0.08±0.01 0.11±0.02 O.Olf
PE plas/PE 1.65±0.16 1.49±0.19 1.18±0.41 O.O1f
LECITHIN 46.15±3.60 47.07±3.61 45.79±3.73 0.50
CHOLINE 59.51±4.74 60.47±5.68 56.26±3.91 0.02g
LECITHIN/CEPHALIN 2.41 ±0.78 2.46±0.52 2.26±0.38 0.60
OUTSIDE 55.62±4.27 56.72± 5.85 51.57±3.96 O.O0Sf
INSIDE 17.32± 1.66 16.94±3.32 18.36±2.58 0.26
LEAFLET (PC + SPH)/(PE + PS) 3.24±0.48 3.55± 1.17 2.89±0.69 0.07
PC/PE 5.79± 1.43 5.62± 1.68 4.45±1.79 0.04
PC/PS 4.41 ±0.65 5.58±2.65 5.29± 1.91 0.30
SPH/PS 1.41±0.44 1.79±1.25 1.29±0.55 0.18
SPH/PE 1.89±0.82 1.88±1.46 1.19±0.73 0.12
ANIONIC/NEUTRAL 0.22±0.02 0.21±0.02 0.24±0.04 0.29
LYSO 2.13±0.54 1.53±0.36 1.29±0.32 0.13
LPC/PC 0.05±0.02 0.03±0.01 0.03±0.00 0.01f
LPE/PEh 0.22±0.19 0.06±0.02 0.39
aPC, phosphatidylcholine; PE, phosphatidylethanolamine; PC plas, phosphatidyl-
choline plasmalogen; PE plas, phosphatidylethanolamine plasmalogen; LECITHIN,
PC + PCplas; CHOLINE, PC + PCplas + SPH (sphingomyeline); LECITHIN/CEPH-
ALIN, (PC + PC plas)/(PE + PE plas); OUTSIDE, PC + SPH; INSIDE, PE + PS
(phosphatidylserine); LEAFLET, (PC + SPH)/(PE + PS); ANIONIC/NEUTRAL, (PI
(phosphatidylinositol) + PS + CL (cardiolipin) + PA (phosphatidic acid) + PG (phos-
phatidylglycerol))/(PC + PC plas + SPH + PE + PE plas); LYSO, LPC (lysophosphati-
dylcholine) + LPE (lysophosphatidylethanolamine). bn = 12. cn = 25. dn = 18. CF prob-
ability ofanalysis ofvariance. IP<0.01. I P<0.05. hNot detected in noninvolved tissues.EX VIVO 31p MRS OF BREAST 697
as a quantitative tool.
31P MR phospholipid analysis permits the characterisation
of the malignant, benign and noninvolved tissue types to the
point that patterns in tissue spectra distinguish malignant
from benign, malignant from noninvolved and benign from
noninvolved (Figure 1). Observations made of differences in
the order of relative intensities of phospholipids in the three
tissue groups implies that differences exist among these tissue
groups and that metabolism of phospholipids in the cell
membrane of malignant tissue is aberrant. It should be noted
that the aberrations in the patterns of signal intensity de-
scribed in the results hold true for the computed mean
relative concentrations.
Fibrocystic disease
Given the definition of fibrocystic disease as a premalignant
process by the American Academy of Pathologists (1986), the
finding that LPC and U independently predicted the classifi-
cations of fibrocystic disease and fibroadenoma in 92% of
the 25 benign cases may indicate that these resonances in
combination are a spectral sign of premalignancy. The
uncharacterised resonance at 0.13 6 has no statistical signifi-
cance in simple comparison of means; however, it is not only
independently significant in differentiating fibrocystic disease
from fibroadenoma, it is significant in differentiating benign
from combined malignant and noninvolved tissue and nonin-
volved from neoplastic tissue in complex contrasts. This
phospholipid awaits isolation and further characterisation.
Phospholipid indices and complex contrasts
Phospholipid indices calculated in this study and presented in
Table IV are designed to facilitate the interpretation of the
spectral data presented in Table I in terms of biochemical
pathways or interrelationships. The indices are practical for
analysing different aspects of phospholipid metabolism. The
plasmalogens, for example, were olly considered in those
indices where their relationship with a regular phospholipid
was established; therefore, the indices PC plas/PC and PE
plas/PE are measures of the relationship of the more reduced
enol-ether-containing plasmalogens to their more oxidised
ester containing analogues in order to reflect the relative
contribution of the metabolic pathways responsible for the
biosynthesis of the ester-containing phosphatides and their
corresponding enol ethers.
The use of complex contrasts in this analysis and in the
general interpretation of MR spectral data is effective in that
complex contrasts can define similarities and differences in
processes or disease states of tissues. Not all of these differ-
ences and similarities can be explained in terms of known
metabolic pathways or known alterations in membrane meta-
bolism with disease. Indices are sometimes used to affirm or
demonstrate trends in data. It should be noted that for the
data presented in this study, when two complex contrasts are
significant for a particular individual metabolite cr index, the
value of the noncombined group is less in one case and
greater in the other. An example is PE, in which the
noninvolved tissue level is significantly diminished compared
to the neoplastic and the malignant is significantly elevated
compared to the nonmalignant. The fact that a contrast
cannot be interpreted in terms of a particular process
should not detract from the value of contrast since it may
represent processes unique to malignant or benign trans-
formation.
Chotine-containing phosphatides
Lysophosphatidylcholine, a product of phosphatidylcholine
metabolism, is significantly decreased in both benign and
malignant breast tissue. This is reflected in the complex
contrast of normal and neoplastic tissues where the relative
concentration of LPC in neoplastic tissues is depressed.
Yamamoto and Ngwenya (1987) have reported that cancer-
ous tissues release acyl-lysophospholipids as degradation pro-
ducts ofacyl-phospholipids, such as those containing choline.
The reduction in the relative levels of LPC in the neoplastic
tissues suggests that there is an increase in the turnover of
this acyl-lysophospholipid compared to noninvolved tissues.
Phosphatidylcholine plasmalogen (an alkyl-phospholipid),
was significantly elevated in the malignant tissues compared
to benign. Snyder and Wood (1968) demonstrated that
malignant tissues release alkyl-phospholipids as degradation
products of cell membranes. The complex contrast showing
malignant tissue to be elevated vs nonmalignant at this reson-
ance was significant which further distinguishes the pheno-
menon as an effect of malignancy.
The two major choline containing phospholipids, PC and
SPH, studied as the index, OUTSIDE, represent the cell
membrane's major outer leaflet phospholipid components.
The identity of PC and SPH as outer leaflet components in
malignant tissues (Widnell et al., 1968) and other mammalian
cells (Rothman et al., 1977), and their position in the MR
spectrum (Meneses et al., 1988) are well established. This
index is diminished in the malignant tissue compared with
the benign, which implies that the choline incorporated into
the phospholipids is inhibited in the malignant tissue or that
the choline is being utilised in other processes. This finding is
further confirmed in the complex contrasts of this index
which shows the index to be significantly diminished in
malignant tissue compared to nonmalignant and to be signifi-
cantly elevated in the benign tissue compared to the combin-
ed inalignant and noninvolved. This alteration in membrane
asymmetry, specifically the components of the outer leaflet,
may be a result of the production of degradation or substitu-
tion products, i.e. lysophosphatidylcholine and PC plasma-
logen.
Ethanolamine-containing phosphatides
The relative concentration of phosphatidylethanolamine is
significantly enhanced in malignant tissue compared to
benign and noninvolved. This elevation is confirmed in the
complex contrast of malignant tissue against nonmalignant
tissue which adds to a previous finding (Merchant et al.,
1988) where the chemical residues of phosphatidylethanol-
amine, phosphorylethanolamine, glycerol 3-phosphoryletha-
nolamine and a-glycerolphosphate were significantly elevated
in malignant human breast tissues compared with benign and
noninvolved tissues. This constellation implies that all the
metabolites in phosphatidylethanolamine metabolism are
elevated and is confirmed by the important role that PE has
been found to play in the modification of membrane shape in
malignant tissues (Cullis et al., 1985). The presence of trace
amounts of LPE in neoplastic tissues substantiates this con-
clusion.
The elevation of phosphatidylethanolamine and the reduc-
tion in choline-containing phosphatides SPH and PC,
responsible for the bulk of membrane asymmetry in human
tissues (Rothman et al., 1977), provides a basis for study of
changes in membrane fluidity and noncompensatory changes
in membrane phospholipid composition with disease.
Otherphosphatides
Phosphatidylinositol was significantly elevated in malignant
tissues compared with benign, but it did not show significant
difference with the normal tissue in simple comparison as a
consequence of the conservative statistical methods used. PI,
however, can differentiate malignant tissue from nonmalig-
nant and benign tissue from combined malignant and nor-
mal. The simple observation in the spectra that a difference is
present in the relative spectral PI signal intensity can be
attributed to the activation of protein kinase C pathway in
malignant tissues since PI is one of the activators of this
pathway (Turner et al., 1985; Price et al., 1989).
We conclude that qualitative and quantitative analysis of
the 31P MR phospholipid profiles of human breast tissues
utilising the described techniques is a worthwhile addition to698 T.E. MERCHANT et al.
MR spectroscopic analysis of diseased human breast tissues.
The value of MR spectral data has been demonstrated by
predicting the benign tissue histology in 92% of cases.
This research was supported by the intramural resources of the
Pathology Institute, University of Utrecht and the Chicago College
of Osteopathic Medicine.
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